Ex vivo expansion of human peripheral blood natural killer cells and cytotoxic T lymphocytes from lung cancer patients

Nhung,Hoang  Thi My; Anh,Bui  Viet; Huyen,Truong  Linh; Hiep,Doan  Trung; Thao,Chu  Thi; Lam,Phung  Nam; Liem,Nguyen  Thanh

doi:10.3892/ol.2018.8029

Ex vivo expansion of human peripheral blood natural killer cells and cytotoxic T lymphocytes from lung cancer patients

Authors:
- Hoang Thi My Nhung
- Bui Viet Anh
- Truong Linh Huyen
- Doan Trung Hiep
- Chu Thi Thao
- Phung Nam Lam
- Nguyen Thanh Liem
View Affiliations

Affiliations: Department of Stem Cell and Immune Cell, Vinmec Research Institute of Stem Cells and Gene Technology, Hanoi 100000, Vietnam, Department of Oncology, Vinmec International Hospital, Hanoi 100000, Vietnam
Published online on: February 12, 2018 https://doi.org/10.3892/ol.2018.8029
Pages: 5730-5738
Copyright: © Nhung et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common type of cancer with the highest cancer-associated mortality rates worldwide, as well as in Vietnam. Numerous studies have demonstrated that higher numbers and higher rate of activity of infiltrating natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) in the tumor are closely correlated with positive prognosis, tumor size decrease and longer survival of lung cancer patients. In the present study, the effectiveness of BINKIT® kit in the ex vivo expansion of NK cells and CTLs in the peripheral blood of 7 patients aged between 30 and 84 years with metastatic lung cancer was evaluated. After 21 days of culture, the average number of CTLs (CD3+CD8+) increased by 742.3‑fold in the CTL culture, accounting for 72.2% of the cultured cell population, and the mean cell viability was 95.7%. In the NK cell culture, the average number of NK cells (CD3‑CD56+) increased by 637.5‑fold, accounting for 84.3% of the cultured cell population, with an average viability of 94.7%. The percentage of active NK cells (CD3‑CD56+ bright) was 82.1%, which increased by 408.9‑fold. Notably, a close correlation was identified between the numbers of cytokine‑induced killer (CD3+CD56+) and NK (CD3‑CD56+) cells in the NK cell culture (P<0.05). In the two culture conditions (namely NK cell and CTL cultures), no clear correlation was identified between the rate of initial immune cells in the peripheral blood and the corresponding number following ex vivo expansion (P>0.05). These results revealed that the method of expansion and activation of NK cells and CTLs from peripheral blood was successfully applied using BINKIT, and reached the requirements for clinical applications in cancer treatment in Vietnam.

View Figures

View References

1	Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. IARC; Lyon, France: 2013
2	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
3	Dudley ME and Rosenberg SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 3:666–675. 2003. View Article : Google Scholar : PubMed/NCBI
4	Terunuma H: Autologous immune enhancement therapy for cancer-our experience since 2004. J Stem Cells Regen Med. 8:205–206. 2012.PubMed/NCBI
5	Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT and Herberman RB: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 5:1303–1315. 2005. View Article : Google Scholar : PubMed/NCBI
6	Kalos M and June CH: Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 39:49–60. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cooper MA, Fehniger TA and Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol. 22:633–640. 2001. View Article : Google Scholar : PubMed/NCBI
8	Screpanti V, Wallin RP, Ljunggren HG and Grandien A: A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol. 167:2068–2073. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, Jack RW, Stoitzner P and McLellan AD: NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol. 192:2514–2521. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sutlu T and Alici E: Natural killer cell-based immunotherapy in cancer: Current insights and future prospects. J Intern Med. 266:154–181. 2009. View Article : Google Scholar : PubMed/NCBI
11	Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H and Blankenstein T: A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8⁺ T cells. Cancer Res. 63:4095–4100. 2003.PubMed/NCBI
12	Maher J and Davies ET: Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer. 91:817–821. 2004. View Article : Google Scholar : PubMed/NCBI
13	Weigelin B, Krause M and Friedl P: Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol Lett. 138:19–21. 2011. View Article : Google Scholar : PubMed/NCBI
14	Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML and Sykulev Y: Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 102:pp. 6437–6442. 2005; View Article : Google Scholar : PubMed/NCBI
15	Ratner A and Clark WR: Role of TNF-alpha in CD8⁺ cytotoxic T lymphocyte-mediated lysis. J Immunol. 150:4303–4314. 1993.PubMed/NCBI
16	Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, et al: NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol. 182:3530–3539. 2009. View Article : Google Scholar : PubMed/NCBI
17	Weng D, Song B, Durfee J, Sugiyama V, Wu Z, Koido S, Calderwood SK and Gong J: Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer. 129:1990–2001. 2011. View Article : Google Scholar : PubMed/NCBI
18	Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE and Gottschalk S: HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 16:474–485. 2010. View Article : Google Scholar : PubMed/NCBI
19	Cho D and Campana D: Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 29:89–96. 2009. View Article : Google Scholar : PubMed/NCBI
20	Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, Christensson B and Dilber MS: A new method for in vitro expansion of cytotoxic human CD3-CD56⁺ natural killer cells. Hum Immunol. 62:1092–1098. 2001. View Article : Google Scholar : PubMed/NCBI
21	Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH and Campana D: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69:4010–4017. 2009. View Article : Google Scholar : PubMed/NCBI
22	Torelli GF, Rozera C, Santodonato L, Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, et al: A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. Blood Transfus. 13:464–471. 2015.PubMed/NCBI
23	Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, et al: Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol. 3:1182013. View Article : Google Scholar : PubMed/NCBI
24	Subramani B, Ratnavelu K, Pullai CR, Krishnan K, Sugadan SD, Deng X and Hiroshi T: Autologous immune enhancement therapy: A case report of a stage IV colonic cancer. Oncol Lett. 5:1611–1614. 2013. View Article : Google Scholar : PubMed/NCBI
25	Dedeepiya V, Terunuma H, Manjunath S, Senthilkumar R, Thamaraikannan P, Srinivasan T, HelenReena C, Preethy S and Abraham S: Autologous immune enhancement therapy for cancer using NK cells and CTLs without feeder layers; our six year experience in India. J Stem Cells Regen Med. 7:952011.PubMed/NCBI
26	Terunuma H, Deng X, Nishino N and Watanabe K: NK cell-based autologous immune enhancement therapy (AIET) for cancer. J Stem Cells Regen Med. 9:9–13. 2013.PubMed/NCBI
27	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
28	Topalian SL, Muul LM, Solomon D and Rosenberg SA: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 102:127–141. 1987. View Article : Google Scholar : PubMed/NCBI
29	Dudley ME, Wunderlich JR, Shelton TE, Even J and Rosenberg SA: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 26:332–342. 2003. View Article : Google Scholar : PubMed/NCBI
30	Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, et al: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 107:1325–1331. 2006. View Article : Google Scholar : PubMed/NCBI
31	Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G and Aarvak T: Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods. 355:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
32	Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW and Khanna R: Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS immune cell serum replacement. Clin Transl Immunol. 4:e312015. View Article : Google Scholar
33	Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M and Zimmer J: Human CD56bright NK Cells: An Update. J Immunol. 196:2923–2931. 2016. View Article : Google Scholar : PubMed/NCBI
34	Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T and Bowness P: CD56^bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J Immunol. 179:89–94. 2007. View Article : Google Scholar : PubMed/NCBI